NanoCor Therapeutics

NanoCor Overview NanoCor Therapeutics, Inc. is a biotechnology company founded to create a viable intracellular genetic protein therapy for the treatment of Chronic Heart Failure (CHF). The company was spun off from Asklêpios BioPharmaceutical, Inc. in November 2005. NanoCor’s initial focus is the commercial development of a non-invasive treatment for CHF. NanoCor’s therapeutic is comprised of the delivery of a proprietary gene developed at the Massachusetts General Hospital and the University of Cincinnati. The gene will be delivered with AskBio’s proprietary Biological NanoParticle (BNP™) and the Self-Complementary Vector technologies, which are derived from human adeno-associated virus vectors (rAAV). The company’s lead therapeutic is Carfostin™. NanoCor’s proprietary BNP™ delivery technology will allow selective and highly efficient delivery of Carfostin™ to the heart muscle cells of patients with progressive CHF and result in long-term and safe therapeutic protein expression in the heart, an absolute prerequisite for successful clinical application of a DNA-based therapeutic. Carfostin™ will not only improve the contractile function of the failing heart muscle, but will also achieve additional therapeutic effects by remodeling its structure to counteract the crippling effects of CHF on the heart. NanoCor’s BNP™ technology is unique in that it allows targeted, non-invasive delivery of the therapeutic to the heart. Non-invasive delivery provides many advantages over other competing technologies currently under development. Once in the heart, Carfostin™ will use the heart muscle as a bioreactor to provide sustained protein expression.
	About Nanocor
		NanoCor's Mission NanoCor Overview Research and Development . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	Contact Us
		870 Martin Luther King Jr. Blvd. Chapel Hill, NC 27514 (919) 942-0252 smikhail@nanocorthx.com . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

NanoCor Therapeutics, Inc. is engaged in the development of novel therapeutics for the treatment of various cardiovascular diseases at the molecular level. NanoCor’s lead therapeutic is Carfostin™, an intracellular protein therapeutic for the treatment of Chronic Heart Failure (CHF). Carfostin™ is comprised of the delivery of a therapeutic gene, protein Phosphatase-1 Inhibitor-1 (I-1) with the use of Biological NanoParticles (BNPs™) and the Self-Complementary Vector Technology. This novel approach, which represents an important adjunct to existing therapies, will provide a non-invasive treatment for these patients and advance the current standard of care.